January 20, 2017
Merck will pay Bristol-Myers Squibb $625 million to end an ongoing intellectual property battle over an immunotherapy cancer treatment, the companies announced on Friday, ending multiple cases including three lawsuits in Delaware federal court and setting up a 10-year licensing agreement.
March 31, 2016
A Delaware federal judge on Tuesday refused to dismiss a suit by Bristol-Myers Squibb accusing Merck of infringing a patent for its immunotherapy cancer treatment, saying that although the patent is directed to a natural phenomenon, further discovery is needed to determine if it is invalid.
July 07, 2015
Bristol-Myers Squibb Co. went after Merck and Co. in Delaware federal court Tuesday for allegedly infringing on its immunotherapy cancer treatment, filing the suit on the same day that the U.S. Patent and Trademark Office granted Bristol-Myers a patent for the process.